Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 21 von 4501
Gene therapy for cancer
The Lancet (British edition), 1992-03, Vol.339 (8795), p.715-721
1992
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Gene therapy for cancer
Ist Teil von
  • The Lancet (British edition), 1992-03, Vol.339 (8795), p.715-721
Ort / Verlag
London: Elsevier Ltd
Erscheinungsjahr
1992
Quelle
EBSCOhost Business Source Ultimate
Beschreibungen/Notizen
  • The molecular basis of cancer is now understood to involve activation of dominant oncogenes and inactivation of tumour suppressor genes, and these genetic events may represent novel targets for cancer therapy. This review focuses on the potential use and ethical implications of gene transfer to alter the behaviour of somatic cells in cancer patients. Antisense nucleic acids and ribozymes represent informational drugs that may be used to modulate the expression of selected genes and suppress malignant behaviour in cancer cells. Genetic immunomodulation by introducing genes for cytokines into cancer cells or lymphocytes can stimulate a cytotoxic immune response against the tumour. Gene transfer techniques can be applied to target prodrug activation specifically to tumour cells and also to protect normal tissues against toxic chemotherapy. Gene replacement therapy could even be used to restore the function of defective tumour suppressor genes. Lancet 1992: 339: 715-21.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX